Dr. Gill's primary research interest is in studying novel targets that are expressed both in tumor blood vessels as well as the tumor cell. He has demonstrated the ability to identify and validate novel targets, develop novel target therapeutics and collaborate with clinical investigators to conduct early stage clinical trials.
Dr. Gill has a strong history of clinical investigations and drug development. His clinical investigations led to the approval of three cancer drugs by the FDA. He also served on the advisory panel for the FDA advisory committee on biologics. Over the past several years his work has focused on the identification of novel cancer and cancer blood vessel targets, validation of the targets in various model systems including genetic mouse models.